ReviewCurrent urology reports2026
Tibial Nerve Stimulation: Recent Progress and Challenges.
Review in Current urology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines the evolution, mechanisms of action, clinical efficacy, and future directions of tibial nerve stimulation (TNS) in the management of overactive bladder (OAB). We sought to clarify how percutaneous (PTNS), transcutaneous (TTNS), and implantable (ITNS) modalities compare in efficacy, safety, durability, and practical application relative to other advanced therapies. RECENT
findingsContemporary randomized trials, cohort studies, and meta-analyses demonstrate pooled response rates of approximately 60–80% across TNS modalities with meaningful improvements in urgency, frequency, nocturia, urgency urinary incontinence, and quality of life. TTNS shows comparable short-term efficacy to PTNS with practical advantages, and ITNS devices demonstrate durable outcomes and reduced treatment burden. Comparative data suggest non-inferior efficacy to sacral neuromodulation and onabotulinumtoxinA with favorable safety profiles. TNS represents an effective, minimally invasive neuromodulatory strategy for OAB. Implantable and closed-loop systems may further improve adherence and long-term outcomes, warranting continued head-to-head and parameter-optimization studies.
Indexed as
Identifiers
41989679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.